Rafael pharmaceuticals announces ongoing successful enrollment and opening of additional sites for phase 2 clinical trial of cpi-613® (devimistat) in combination with gemcitabine and cisplatin in patients with biliary tract cancer

Cranbury, n.j., jan. 18, 2022 (globe newswire) -- rafael pharmaceuticals, inc. (“rafael” or the “company”), a company focused on the growing field of cancer metabolism-based therapeutics, today announced the ongoing successful enrollment rate of its phase 2 clinical trial for cpi-613® (devimistat) in combination with gemcitabine and cisplatin in patients with biliary tract cancer. the multicenter trial is for patients with locally advanced unresectable or metastatic biliary tract cancer who have had no prior treatment. the trial is currently open through the university of michigan health rogel cancer center as an investigator-sponsored trial. the trial is also open at fred hutchinson cancer research center and ut southwestern simmons cancer center. rafael is also launching additional sites for the trial at northwestern university lurie cancer center, uh seidman cancer center, the university of arizona cancer center, university of wisconsin carbone cancer center, vanderbilt-ingram cancer center, atlantic health system cancer care, and allegheny health network cancer institute.
RFL Ratings Summary
RFL Quant Ranking